Taiwan Smart Healthcare After TFDA Certification: New Opportunities and Data Interoperability Outlook

Details

The certification of wearable devices such as Apple Watch and ASUS VivoWatch by the Taiwan Food and Drug Administration (TFDA) marks a significant turning point for smart healthcare in Taiwan. This accreditation means that ECG and blood pressure monitoring data are recognized not merely as reference information, but as 'medical assistance' data with clinical diagnostic value. Currently, through centers established by the Ministry of Health, such as the 'Clinical AI Certification Center,' collaboration is accelerating between 16 key hospitals (including National Taiwan University Hospital) to certify and implement AI medical software (SaMD). Leveraging this environment, major ICT companies like Inwin and Foxconn can commercialize technologies such as AI image interpretation and remote monitoring. The core focus is shifting the business model from single hardware sales to high-value subscription-based health management services. By gaining medical device status, devices can connect with hospital systems and insurance providers, transforming massive medical data into precise algorithmic assets. Furthermore, utilizing the FHIR international standard enables seamless data interoperability—from in-hospital diagnosis to home care—building a complete digital ecosystem. Taiwan plans to use its mature clinical environment for field validation, aiming to export its technology platform overseas, transitioning from a mere hardware supplier to a data-driven medical decision partner.